This urged the design of TNF-neutralizing agents, like the TNFR2-Fc Enbrel (/Etanercept) or TNF-neutralizing antibodies, that are now successfully used worldwide to limit Rheumatoid Arthritis (RA), psoriasis and Inflammatory Bowel Disease (IBD) [36]. This evidence concerns the gene TNF and psoriasis.